Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib vs Palbociclib and Cemiplimab in Advanced Dedifferentiated Liposarcoma
NCT05694871Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2023
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in dedifferentiated liposarcoma (DDL), sponsored by Cancer and Leukemia Group B. Started Jun 2023; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT05694871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694871.